Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)
Status:
Unknown status
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of Fludarabine, Adriamycin
and Dexamethasone (FAD) as first line therapy in patients with Peripheral T-cell lymphomas
(PTCL). 30 patients will be treated into this study.